1Zelefsky MJ,Whitmore WF Jr.Long-term results of retropubic permanent 125Iodine implantation of the prostate for clinically localized prostatic cancer[J].J Urol,1997,158:23-29.
2Ellis WJ.Prostate brachytherapy[J].Cancer Met Rev,2002,21:125-129.
3Nag S,Beyer D,Friedland J,et al.American Brachytherapy Society recommendations for transperineal permanent brachytherapy of prostate cancer[J].Int J Radiat Oncol Bios Phys,1999,44:789-799.
4Nag S.Brachytherapy for prostate cancer:Summary of American Brachytherapy Society recommendations[J].Semin Urol Oncol,2000,18:133-136.
6Merrick GS,Wallner KE,Butler WM.Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland[J].J Urol,2003,169:1643-1652.
7Merrick GS,Bulter WM.Modified uniform seed loading for prostate brachytherapy:rationale,design and evaluation[J].Tech Urol,2000,6:78-83.
8Prestidge BR,Bice WS,Kiefer E J,et al.Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy[J].Int J Radiat Oncoi Biol Phys,1998,40:1111-1115.
9Waterman FM,Yue N,Reisinger S,et al.Effect of edema on the post-implant dosimetry of an 1-125 prostate implant:A xase study[J].Int J Radiat Oncol Biol Phys,1997,38:335-339.
10Norderhaug I,Dahl O,Heikkila Reino,et al.Brachytherapy for prostate cancer:A systematic review of clinical and cost effectiveness[J].Euro Urol,2003,44:40-46.
二级参考文献33
1Merrick GS, Bulter WM, Wallner KE, et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology, 2002, 60: 650-655.
2Celebrezze JP, Medich DS. Rectal ulceration as a result of prostatic brachytherapy: a new clinical problem :report of three cases. Dis Colon Rectum, 2003, 46: 1277-1279.
3Zelefsky MJ, Whitmore WF Jr.Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol, 1997, 158: 23-29.
4Holm HH, Juul N, Pedersen JF, et al. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol, 1983, 130: 283-286.
5Nag S. Brachytherapy for prostate cancer: Summary of American Brachytherapy Society recommendations. Semin Urol Oncol, 2000, 18: 133-136.
6Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Bios Phys, 1999, 44: 789-799.
7Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol, 2003, 169:1643-1652.
8Merrick GS,Bulter WM. Modified uniform seed loading for prostate brachytherapy: rationale, design and evaluation. Tech Urol, 2000, 6: 78-84.
9Prestidge BR, Bice WS, Kiefer EJ, et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys, 1998, 40: 1111-1115.
10Waterman FM, Yue N, Reisinger S, et al. Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study. Int J Radiat Oncol Biol Phys, 1997, 38: 335-339.
6Norderhaug I, Dahl O, Hdkkila Reino, et al. Brachytherapy for prostate cancer:A systermatic review of clinical and cost effectiveness[ J ]. Euro Urol,2003 ,44 :40-46.
7Portess D I, Bauer G, Hill M A, et al. Low-dose irradiation of nontrans- formed cells stimulates the selective removal of precancerous cells via intercellular induction of apoptosis [ J ]. Cancer Res, 2007,67 ( 3 ) : 1246-1253.
8An J, Chervin AS, Nie A, et al. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor[ J]. Oncogene,2007,26 (5) :652-661.
9Carroll PR. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients:preoperative application in prostate cancer[ J]. Urol Oncol,2003,21 (6) :484-485.
10Ellis WJ. Prostate brachytherapy [ J ]. Cancer Met Rew,2002,21 : 125 - 129.
